Advertisement

Topics

Alizyme Therapeutics Limited Company Profile

05:19 EDT 17th October 2017 | BioPortfolio

Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory bowel disease and mucositis, a serious side effect of cancer therapy.

Alizyme takes drug product candidates from an early stage into clinical development with the objective of demonstrating their efficacy in patients and providing a comprehensive data package to support the further development and commercialisation of the drug. Alizyme owns the intellectual property rights to all four drug products currently in clinical trials and has an exclusive worldwide licence to the COLAL™ drug delivery system.



At a suitable stage Alizyme aims to license its products to pharmaceutical companies that have the ability to complete the clinical development of the product, to gain approval from the regulatory authorities and to successfully market the product.



Alizyme has developed its business with a high emphasis on outsourcing, controlled by its core management team and specialist advisors. Rather than establish its own laboratories and development facilities, it has worked with collaborators and service providers such as contract research organisations. This has the benefit of allowing Alizyme to focus its investment onto its development programmes in a cost effective way.

Location

Granta Park, Great Abingdon
Cambridge
Cambridgeshire
CB1 6GX
United Kingdom

Contact

Phone: 44 1223 896000
Fax: 44 1223 896001
Email: info@alizyme.co.uk


News Articles [424 Associated News Articles listed on BioPortfolio]

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Summit Therapeutics PLC (SMMT) and Orexigen Therapeutics (OREX) Head to Head Review

Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, in...

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...

Quotient Limited to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

JERSEY, Channel Islands, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive...

Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix Pharmaceuticals Limited

MELBOURNE, Australia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have be...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

Clinical Trials [118 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1238 Associated Companies listed on BioPortfolio]

Alizyme Therapeutics Limited

Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related diseas...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Alizyme plc

Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK. We are focused on developing products for the treatment and management of gastrointestinal disorders involving in...

Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to i...

Circadian Technologies Limited

Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs),...

More Information about "Alizyme Therapeutics Limited" on BioPortfolio

We have published hundreds of Alizyme Therapeutics Limited news stories on BioPortfolio along with dozens of Alizyme Therapeutics Limited Clinical Trials and PubMed Articles about Alizyme Therapeutics Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alizyme Therapeutics Limited Companies in our database. You can also find out about relevant Alizyme Therapeutics Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...


Corporate Database Quicklinks



Searches Linking to this Company Record